United States, Ex Rel. Hart v. McKesson Corp.

96 F.4th 145
CourtCourt of Appeals for the Second Circuit
DecidedMarch 12, 2024
Docket23-726
StatusPublished
Cited by8 cases

This text of 96 F.4th 145 (United States, Ex Rel. Hart v. McKesson Corp.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States, Ex Rel. Hart v. McKesson Corp., 96 F.4th 145 (2d Cir. 2024).

Opinion

23-726-cv United States, et al., ex rel. Hart v. McKesson Corp., et al.

UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT

August Term, 2023

(Argued: November 28, 2023 Decided: March 12, 2024)

Docket No. 23-726-cv

UNITED STATES OF AMERICA, ET AL., EX REL. ADAM HART,

Plaintiffs-Appellants,

— v. —

MCKESSON CORPORATION, MCKESSON SPECIALTY DISTRIBUTION LLC, MCKESSON SPECIALTY CARE DISTRIBUTION CORPORATION,

Defendants-Appellees.*

* The Clerk of Court is respectfully directed to amend the official caption in this case to conform with the caption above.

1 B e f o r e:

LYNCH and PARK, Circuit Judges, and WILLIAMS, District Judge.**

__________________

Adam Hart brought a qui tam action under the federal False Claims Act (the “FCA”) and the FCA analogues of several states and the District of Columbia against a pharmaceutical distributor, McKesson. Hart alleged that McKesson provided two business management tools to its customers without charge, in exchange for those customers’ commitments to purchase drugs from McKesson, conduct that he argues violated the federal anti-kickback statute (the “AKS”) and several analogous state anti-kickback statutes. The district court (Abrams, J.) dismissed Hart’s FCA claim because it concluded that Hart failed to allege sufficient facts to suggest that McKesson acted “willfully,” as required under the AKS. It dismissed the remaining claims under the state FCA analogues on the ground that those claims were premised solely on a violation of the federal AKS. We hold that the district court correctly concluded that to act “willfully” under the federal AKS, a defendant must act knowing that its conduct is in some way unlawful, and that Hart failed to plead sufficient facts to meet that standard. We also hold, however, that the district court erred in concluding that Hart’s remaining claims were premised solely on a violation of the federal AKS. Accordingly, we AFFIRM the district court’s dismissal of Hart’s federal FCA claim, VACATE the dismissal of the remaining claims, and REMAND for further proceedings.

ANDREW C. SHEN, Kellogg, Hansen, Todd, Figel & Frederick, P.L.L.C. Washington, DC (James M. Webster, David L. Schwarz, Bradley E. Oppenheimer, Grace W. Knofczynski, Kellogg, Hansen, Todd,

** Judge Omar A. Williams of the United States District Court for the District of Connecticut, sitting by designation.

2 Figel & Frederick, P.L.L.C., Washington, DC; Stephen S. Hasegawa, Phillips & Cohen LLP, San Francisco, CA; Ari Yampolsky, Constantine Cannon LLP, San Francisco, CA, on the brief), for Plaintiffs-Appellants.

MARK MOSIER, Covington & Burling LLP, Washington, DC (Krysten L. Rosen Moller, Ethan M. Posner, Nicholas Pastan, Covington & Burling LLP, Washington, DC; S. Conrad Scott, Covington & Burling, New York, NY, on the brief), for Defendants-Appellees.

GERARD E. LYNCH, Circuit Judge:

In this qui tam action, Adam Hart sued McKesson Corporation, McKesson

Specialty Distribution LLC, and McKesson Specialty Care Distribution

Corporation (together, “McKesson”) under the federal False Claims Act (the

“FCA”), 31 U.S.C. § 3729 et seq., and the FCA analogues of 27 states and the

District of Columbia. Hart, a former McKesson Business Development Executive,

alleges that McKesson, a pharmaceutical wholesaler, offered its customers free

access to two valuable business management tools to induce those customers to

purchase drugs from McKesson. He argues that McKesson’s use of the tools

operated as a kickback under the federal Anti-Kickback Statute (the “AKS”), 42

U.S.C. § 1320a-7b, and similar anti-kickback laws of various states and the

District of Columbia.

3 The United States District Court for the Southern District of New York

(Ronnie Abrams, J.) dismissed Hart’s federal claim, concluding that Hart had

failed to allege that McKesson acted with the requisite scienter under the AKS. It

dismissed his remaining claims on the ground that they were all premised on a

violation of the federal AKS.

As explained below, we agree with the district court that to violate the

federal AKS, a defendant must act knowing that its conduct is, in some way,

unlawful, and that Hart failed to allege facts sufficient to satisfy that standard.

We disagree, however, with the district court’s conclusion that Hart’s claims

under the FCA analogues of several states and the District of Columbia were

premised solely on a violation of the federal AKS. Accordingly, we AFFIRM the

district court’s dismissal of Hart’s federal claim, VACATE the dismissal of Hart’s

remaining claims, and REMAND for further proceedings consistent with this

opinion.

4 BACKGROUND

I. Factual Background1

McKesson is a large wholesale pharmaceutical distributor that sells

products across the United States. It provides drugs and other medical supplies

to various health care providers, including oncology providers. McKesson

includes two divisions that serve oncology customers – the U.S. Oncology

Network (“USON”), which offers tools and services to member health care

practices in exchange for management fees, and the Open Market Division,

which operates as a traditional drug wholesaler that purchases drugs from

manufacturers and sells them at a markup to health care practices.

Oncology practices often obtain specialty drugs from wholesalers like

McKesson. When an oncology practice buys a specialty drug from a wholesaler,

it bills its patient’s insurer for the cost of the drug. Medicare and Medicaid are

federally funded health insurance programs that are major payors for oncology

drugs procured in that fashion. Those programs reimburse health care providers

1 When reviewing the district court’s grant of a motion to dismiss, we – like the district court – take the plaintiff’s well-pleaded allegations as true and draw all reasonable inferences in his favor. United States ex rel. Foreman v. AECOM, 19 F.4th 85, 104 (2d Cir. 2021).

5 for such drugs at standardized rates set by Medicare. Because the reimbursement

rates do not change based on what a given provider paid for the drugs, each

provider bears the risk that the reimbursement rate for a given drug will fall

below its costs. If the reimbursement rate exceeds a provider’s costs, however, the

provider can profit from the difference.

McKesson offers two tools (the “Business Management Tools”) to help

providers maximize their profits and mitigate the risk that the reimbursement

rate will fall below the actual cost they paid for drugs. The first tool, the Margin

Analyzer, evaluates sets of “therapeutically interchangeable” drugs by

comparing McKesson’s price for each drug to publicly available Medicare

reimbursement rates for that drug. App’x 277–78, ¶¶ 63, 65. Using the Margin

Analyzer, a medical provider can thus compare drugs that McKesson categorizes

as interchangeable to determine which treatment option provides the highest

profit margin based on how each drug’s reimbursement rate measures up to

McKesson’s prices. The Margin Analyzer does not evaluate the comparative

medical benefits of the drugs that it analyzes, nor does it evaluate which drug

would provide the least expensive option for a given patient. Instead, according

to Hart, the tool’s “sole function is to identify which among several purportedly

6 equivalent drugs will earn a physician practice – and, not coincidentally,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
96 F.4th 145, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-ex-rel-hart-v-mckesson-corp-ca2-2024.